Akribion Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $8.6Mattributed |
|---|---|
| Latest round | seed, $8.6M, 2025-02-15attributed |
| Founded | 2022 |
| Headquarters | Zwingenberg, Germany |
| Industry | bio |
| Stage | seed |
| Website | akribion-therapeutics.com |
Akribion develops the G-dase E RNA-guided nuclease for programmable cell depletion in precision oncology. It targets clinicians treating HPV-induced head-and-neck cancers initially, with broader oncology potential. Differentiator: single-nucleotide specificity and rapid retargeting via gRNA exchange.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-15 | seed | $8.6M | undisclosed |
Detected tech stack
PHP 8.2.31, WordPress 6.9.4, Apache HTTP Server 2.4.67, Magnific Popup 8.45.1, UNIX, MySQL, apache 2.4.67, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $8.6M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $8.6M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | akribion-therapeutics.com, read 2026-05-02 |
| Description | self-reported | akribion-therapeutics.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.